methylphenidate: The patients with ADHD will receive 12-week treatment with methylphenidate.
Study summary
To explore the relationship of treatment-related changes in electrophysiology and those in metabolomics for identification of the underlying metabolic mechanisms for the electrophysiological effects of methylphenidate in children with ADHD.
Eligibility
Sex
ALL
Min age
6 Years
Max age
18 Years
Healthy volunteers
Accepted
1. Patients with ADHD
1. Inclusion Criteria
* Patients, aged 6 to 18 years, meet the DSM-5 diagnostic criteria for ADHD.
* At baseline, patients have a Clinical Global Impressions-ADHD-Severity (CGI-ADHD-S) score greater than 4.
* Patients have a Full IQ (FIQ) score greater than 80.
2. Exclusion Criteria
* Patients have a major psychiatric disorder, such as autism spectrum disorder, schizophrenia, affective disorders, or substance use disorders.
* Patients have a major disorder of central nervous system, such as epilepsy.
* Patients have a major systemic disease, such as diabetes mellitus or cardiovascular diseases.
* Patients have ever received any medication to treat the clinical symptoms of ADHD.
2. Neurotypical participants:
1. Inclusion Criteria
* aged 6 to 18 years
* All of the neurotypical participants have no psychiatric disorder in lifetime according to the diagnostic criteria of DSM-5.
2. Exclusion Criteria
* participants have any disorder of central nervous system or major systemic disease
* participants have ever taken any psychotropic drug, or who have FIQ scores less than 80, will be excluded from the present study.
Primary outcome measure(s)
Diagnostic interview — 1 hour We will interview all the participants and their parents to examine whether the participants have any psychiatric disorder by employing the Kiddie Epidemiologic version of the Schedule for Affective Disorders and Schizophrenia (K-SADS-E).
ADHD symptoms — 15 minutes Subjects will be interviewed by ADHD rating scale , which consists of 18 items to measure the symptomatology of ADHD . Each question in this questionnaire is scaled from 0 to 3. The higher the total score, the more severe the symptoms.
Trial sites (1)
Facility
City
Region
Status
National Taiwan University Hospital
Taipei
Taiwan
Recruiting
More National Taiwan University Hospital trials in Taiwan
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
